Becton, Dickinson and Company (NYSE: BDX) trades near $190/share after a mixed year marked by slower growth and higher leverage. The stock has faced pressure as investors look for clearer signs of improvement, although BDX continues to benefit from strong recurring revenue and a highly profitable product mix across its medical and diagnostics segments.
Recently, BDX reported early progress on its cost discipline and efficiency initiatives, which helped support stable margins and more consistent operating performance. Management also highlighted ongoing work on its restructuring program aimed at simplifying the business and building a more predictable earnings base. These developments suggest BDX is working to restore stability after a challenging stretch.
This article outlines where Wall Street analysts believe BDX could trade by 2028. We combined consensus price targets with TIKR’s Guided Valuation Model to map out the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
BDX trades at about $193/share today. The latest analyst average price target is $201/share, which implies roughly 6% upside. This places BDX in the modest upside category since expectations do not point to a major rerating.
Here is the full target range:
- High estimate: $270/share
- Low estimate: $183/share
- Median estimate: $194/share
- Ratings: 4 Buys, 1 Outperform, 9 Holds
Analysts see some room for gains, but the wide spread between estimates shows mixed conviction. For investors, BDX may outperform if margin improvements continue and the balance sheet strengthens. However, the modest upside suggests the market wants clearer evidence of growth before assigning a higher valuation.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
BDX Growth Outlook and Valuation
The company’s forward outlook appears stable based on the assumptions used in the valuation model:
- Revenue is projected to grow 2.6%
- Operating margins are expected to reach 25.4%
- Shares trade near 12.7x forward earnings
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 12.7x forward P E suggests about $230/share by 9/30/28
- That implies around 21% upside, or roughly 7% annualized returns
These numbers point to steady compounding rather than fast acceleration. For investors, BDX looks more like a stable healthcare operator than a high growth story. The stock does not need rapid expansion for returns to work at today’s valuation, as long as earnings remain consistent and the company continues strengthening its balance sheet.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
BDX benefits from several structural strengths that support long term stability. Its consumables-heavy portfolio generates reliable demand, and the company has been focused on tightening expenses and improving operational consistency. These efforts are helping create a more predictable earnings base and improve efficiency across the business.
Management’s emphasis on organizational simplicity, supply chain improvements, and disciplined capital allocation suggests BDX is positioning itself for a more consistent growth trajectory. For investors, these actions indicate that the long term fundamentals remain intact even if near term growth is slower.
Bear Case: Growth and Leverage Concerns
Despite these strengths, BDX faces constraints that limit how quickly the stock can rerate. Revenue growth expectations remain soft, and the company continues to operate with a sizeable debt load that reduces financial flexibility. Some business segments have also shown uneven performance, making it harder for investors to gain confidence in a faster earnings rebound.
For investors, the concern is that stability alone may not be enough to drive stronger upside. Without clearer signs of accelerating earnings or more aggressive balance sheet improvement, BDX may continue trading within a relatively narrow range.
Outlook for 2028: What Could BDX Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 12.7x forward P E suggests BDX could trade near $230/share by 9/30/28. That would represent about 21% total return, or roughly 7% annualized over the next 2.9 years.
While this would mark a steady recovery, the estimate already assumes moderate improvements in margins and continued progress on structural initiatives. To unlock stronger upside, BDX would likely need clearer revenue acceleration or faster balance sheet improvement.
For investors, BDX appears to be a dependable long term healthcare operator with predictable earnings and manageable risks. The potential for outsized returns depends on management delivering above current expectations, particularly in margin expansion and operational efficiency.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
